Brought to you by 
Covidien buys ev3 for $2.5bn in cash
23 Sep 2010
Executive Summary
Covidien Ltd. has agreed to buy cardiovascular/neurology device company ev3 Inc. for $2.5bn. Shareholders will receive $22.50 in cash per share (a 21% premium).
Deal Industry
- Medical Devices
-
Medical Devices
- Implantable Devices
-
Surgical Equipment & Devices
- Minimally or Less Invasive
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Includes Contract
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Covidien buys ev3 for $2.5bn in cash
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice